Cancer Screening Committee
In which cases are long-term and/or broad-based examinations useful for the early detection of cancer? Then when do these so-called screening examinations do more good than harm to those undergoing them? The general population as well as professional circles are confronted by questions about screening for cancer, which again lead to further discussions.
The national Cancer Screening Committee has been set up within the framework of the National Strategy against Cancer. It is devoted to the questions surrounding cancer screening issues. The committee works in a scientifically well-founded, balanced manner and is independent of particular interests or recommendations.
11 August 2021
The Cancer Screening Committee recommends that cervical cancer screening should also include testing for the human papilloma virus (HPV). Women and non-binary persons and transgender men with a cervix who are aged between 30 and 70 years should in the future be able to have a cervical smear with an HPV test every three to five years. Positive test results showing evidence of cell changes should then be confirmed by a cytological examination. The cost of HPV testing should be covered by the statutory health insurance. For the 21-to-29-year age group, the committee recommends, as previously, that screening should consist of a cytological examination.